Valeant Pharmaceuticals Int'l Inc. (VRX) shares dipped 1.63% to $15.13 in mid-morning trading Monday, Nov. 13, after the drug maker launched a $750 million debt offering.
Valeant announced the private offering with notes due in 2025 in a statement Monday. The proceeds from the offering of the existing 5.5% senior secured notes will be used to repay a portion of term loan facilities due in 2022, Valeant said.
In late October, the company announced it was on pace to exceed an earlier goal of paying down $5 billion in debt by February 2018. Valeant still has more than $26 billion in debt, but no obligations until 2020.
Valeant stock has gained 4.27% since the start of the year, compared to the broader S&P 500 Index's 15.3% gain in the same period.
More of What's Trending on TheStreet:
- Bill Gates Buys 25,000 Acres of Land in Arizona to Build 'Smart City'
- GE's Flannery to Sell Locomotives Business, May Exit Baker Hughes
- A Broadcom Director Fight Could Be Next at Qualcomm
- BP CEO: Venezuela Is a Bigger Concern Than the Middle East for Oil Industry